Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction

The clinical successes of chimeric antigen receptor (CAR)-T-cell therapy targeting cell surface antigens in B cell leukaemias and lymphomas has demonstrated the proof of concept that appropriately engineered T-cells have the capacity to destroy advanced cancer with long term remissions ensuing. Neve...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavriil, Artemis, Barisa, Marta, Halliwell, Emma, Anderson, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463974/
https://www.ncbi.nlm.nih.gov/pubmed/32824734
http://dx.doi.org/10.3390/cancers12082326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463974/
https://www.ncbi.nlm.nih.gov/pubmed/32824734
http://dx.doi.org/10.3390/cancers12082326

Ejemplares similares